Furthermore, by directly promoting GBM-initiating cells’ proliferation and migration through the up-regulation of S100A4, these cells induced the transition to a mesenchymal phenotype, favoring cancer invasion and resistance to anti-VEGF therapies [118]. The gene discussed is VEGFA; the disease is glioblastoma.